Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 13,940 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Radiation Exposure
Interventions: lead-free protective drape containing bismuth and antimony (RADPAD®), sterile identical sham drape; Device
Lead sponsor: Yale University; Other
Eligibility: 45 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: New Have, Connecticut

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Nasal Cavity and Paranasal Sinus Carcinoma, Oral Cavity Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Hypopharyngeal Carcinoma, Recurrent Laryngeal Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Carcinoma, Recurrent Oral Cavity Carcinoma, Recurrent Oropharyngeal Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Celecoxib, Placebo, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Preterm Neonates
Interventions: Gradual weaning from Nasal CPAP in preterm neonates; Procedure
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 24 Weeks to 32 Weeks
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir, sitagliptin, metformin, sulphonylurea; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Vestavia Hills, Alabama • Orange, California • Santa Monica, California + 7 more

Conditions: Healthy Adult Male and Female Volunteers
Interventions: Low-frequency whole-body vibration mat; Device
Lead sponsor: Florida International University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypertension
Interventions: Physician-level financial incentives, Practice-level financial incentives, Physician- and practice-level financial incentives; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 12
States / cities: Birmingham, Alabama • Newington, Connecticut • Augusta, Georgia + 9 more

Conditions: Cervical Radiculopathy
Interventions: Ultrasound-guided electrical dry needling, Conventional Physical Therapy; Procedure
Lead sponsor: Liberty University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Macon, Georgia

Conditions: Type 2 Diabetes, Type 2 Diabetes (T2DM)
Interventions: Eroxon®, tadalafil; Device · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Premature Birth
Interventions: Full Term EEG, Facilitated Infant Care; Other · Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 26 Weeks to 42 Weeks
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Newark, New Jersey • New York, New York

Conditions: Enlarged Prostate (BPH), Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions: Ejaculatory-sparing (ES-sparing) HoLEP; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Acupuncture; Other
Lead sponsor: Allina Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Nausea
Interventions: Acupressure expectancy enhancement; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Solid Tumor
Interventions: Stereotactic radiotherapy, Biological: humanized anti-PD-1 monoclonal antibody, Biological: humanized anti-PD-L1 monoclonal antibody; Radiation · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Fomivirsen sodium; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Irvine, California • Los Angeles, California • Pasadena, California + 19 more

Conditions: Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic, Hypoxic-Ischemic Encephalopathy, Ischemic-Hypoxic Encephalopathy
Interventions: Hypothermia, Normothermic Control; Device · Procedure
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 33 Weeks to 35 Weeks
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 18
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 14 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Cognitive Processing Therapy (CPT); Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Hines, Illinois • Madison, Wisconsin

Conditions: Depressive Disorder, Major
Interventions: NMDA Antagonist, CP-101,606 (traxoprodil); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Plaque Psoriasis
Interventions: (CP-6890,550) Tofacitinib, Placebo, (CP-690,550) Tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 5
States / cities: Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more

Conditions: Caries
Interventions: verbal education, verbal education, visual aids, and motivational interviewing; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Up to 6 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Wounded Warrior, Limb Shortening, Amputation
Interventions: Enhanced Fat Grafting, Standard fat graft; Device · Procedure
Lead sponsor: J. Peter Rubin, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Gene Modified T Cells, Gene Modified T Cells and Interleukin 2; Biological
Lead sponsor: Roger Williams Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: New Hartford, New York

Conditions: Binge-Eating Disorder
Interventions: Centanafadine, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 25
States / cities: Phoenix, Arizona • Beverly Hills, California • Encino, California + 21 more

Conditions: Vulvar Lichen Sclerosus
Interventions: StrataMGT, Placebo; Drug
Lead sponsor: Andrew T. Goldstein, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Tampa, Florida • New York, New York

Search by objective public record fields.

Digestive Endoscopy Suite Radiation Controlling Protective Strategies

Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Trial of Weaning of Nasal Continuous Positive Airway Pressure (CPAP)

Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes

Evaluating a Mat-Based Biometric Vibration System for Sleep and Daily Recovery

Financial Incentives to Translate ALLHAT Into Practice: A Randomized Trial

Ultrasound-Guided Electrical Dry Needling for Chronic Cervical Radiculopathy

PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)

Family Nurture Intervention in the CHoNJ NICU

Ejaculatory-Sparing HoLEP vs Standard HoLEP

A Pilot Trial to Assess the Impact of Acupuncture on Post-mastectomy Pain, Nausea, Anxiety and Ability to Cope

Acupressure and Relaxation for Nausea Control

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes

Preemie Hypothermia for Neonatal Encephalopathy

Comparison of Videoconference and Face-to-Face Delivery of Cognitive Processing Therapy for Posttraumatic Stress Disorder

The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

A Strategy to Prevent the Recurrence of Dental Disease in Children Receiving Dental Treatment With General Anesthesia

AMP30: Autologous Fat Grafting, Amputation Sites Pain: Randomized

Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer

Pilot Randomized Controlled Trial of Telemedicine for Individuals With Parkinson Disease in a Rural Population

A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms